Abstract
Importance: Postnatal intensive care for preterm infants born at 22 to 23 weeks' gestation is increasing, although survival rates remain low. Information on outcomes for multiple countries or regions can be important for research, benchmarking, quality improvement, and parental counseling.
Objective: To evaluate survival and major morbidities and their between-network variations in infants born at 22 to 23 weeks' gestation in 11 neonatal networks participating in the International Network for Evaluation of Outcomes (iNeo) in neonates in 12 countries or regions.
Design, setting, and participants: International registry-based cohort study of infants born at 22 to 23 weeks' gestation from January 1, 2015, through December 31, 2021, without major congenital anomalies who were admitted for neonatal intensive care in 11 national or regional neonatal consortia. Data analysis was performed from December 2, 2023, to June 15, 2025.
Exposures: Neonatal consortium and gestational age at birth.
Main outcomes and measures: Survival to neonatal intensive care unit discharge, major neonatal morbidities, and survival without any major morbidities.
Results: A total of 5019 neonates were included (1084 of 4636 neonates [23%] with a maternal age >35 years; 2641 of 5017 neonates [53%] male); among them, 846 neonates were born at 22 weeks' gestation and 4173 were born at 23 weeks' gestation. Variations between contributing networks for perinatal management at 22 and 23 weeks' gestation, respectively, include any antenatal steroids (ranges of 18%-83% and 57%-98%), cesarean birth (0%-42% and 5%-73%), and outborn (0%-26% and 0%-22%). Significant variations between contributing networks for adjusted probabilities of outcomes at 22 and 23 weeks' gestation, respectively, include survival to discharge (95% CIs of 9%-64% and 16%-80%; P < .001), grade 3 or 4 periventricular hemorrhage (PVH) or periventricular leukomalacia (PVL) (severe PVH or PVL: 24%-65% and 18%-56%; P < .001), survival without severe PVH or PVL (7%-53% and 9%-69%; P < .001), treated retinopathy of prematurity among survivors (32%-57% [P = .008] and 16%-48% [P < .001]), bronchopulmonary dysplasia among survivors (for 23 weeks only: 64%-88%; P < .001), and necrotizing enterocolitis (for 23 weeks only: 6%-28%; P < .001). Standardized incidence ratios showed significant differences in survival and major morbidities in some networks compared with a reference population from all other networks.
Conclusions: Substantial international variations were identified in outcomes for infants born at 22 to 23 weeks' gestation who were admitted to 11 neonatal networks in the 12 countries or regions. The variations can be due to differences in systems, care practices, attitudes, and culture; however, identification of variation can help focus efforts toward research aimed at understanding the causal determinants of variation.